Loading...
XKRX
086450
Market cap752mUSD
Oct 08, Last price  
22,400.00KRW
1D
-1.32%
1Q
16.79%
Jan 2017
-60.98%
IPO
-40.27%
Name

Dongkook Pharmaceutical Co Ltd

Chart & performance

D1W1MN
XKRX:086450 chart
P/E
15.31
P/S
1.09
EPS
1,463.52
Div yield, %
0.89%
Shrs. gr., 5y
0.02%
Rev. gr., 5y
10.64%
Revenues
926.88b
+14.12%
180,296,024,780213,086,061,880226,014,177,940259,929,994,536309,690,117,405354,767,875,845400,807,087,433482,280,354,000559,103,459,000594,193,122,000661,647,492,000730,993,597,000812,166,073,000926,883,702,000
Net income
66.02b
+7.84%
22,312,055,73016,763,567,22021,098,324,75027,425,742,72040,659,764,61439,601,738,02546,948,799,03356,312,246,00055,925,025,00050,345,221,00052,895,927,00047,175,203,00061,218,953,00066,020,355,000
CFO
71.99b
-5.38%
14,203,464,12019,860,053,29022,737,479,93027,903,635,67740,283,996,74829,330,523,78734,698,059,58769,391,677,00059,108,279,00044,653,917,00040,909,002,00041,792,951,00076,090,783,00071,994,154,000
Dividend
Dec 29, 2025200 KRW/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

DongKook Pharmaceutical Co., Ltd., established in Seoul, South Korea in 1968, operates as a pharmaceutical company with a broad presence both domestically and globally. Formerly known as UEC & Co., Ltd. until its rebranding in March 1982, the firm manufactures and distributes a diverse array of healthcare products. Its offerings include essential active pharmaceutical ingredients like propofol, streptokinase, and teicoplanin. The company also produces a wide range of finished drug forms such as disposable syringes, tablets, capsules, and topical ointments, in addition to various injectable solutions including small and large volume parenterals, and lyophilized medications. Specific branded injections like Teicon, Durakinase, and Lorelin Depot are also part of its portfolio. Furthermore, DongKook develops and supplies natural product derivatives, featuring black cohosh and magnolia extracts (marketed as ETIZM and TECA), alongside traditional herbal remedies. Its extensive inventory also encompasses general and prescription-based drugs, medical equipment, ethical and beauty products, and specific quasi-drugs, such as the lipossol hydrocare bandage. The company's market reach extends to roughly 40 nations, with substantial exports to regions including Japan, Europe, Central and South America, and India.

Key people

Gi Beom Gwon
Chairman · since 2022
Geun Yeong Lee
Vice President · since 2022
Mun Hwan Jung
Managing Director · since 2022
Jae Wuk Lee
Managing Director · since 2021
Jeong Mu Huh
Managing Director · since 2023
Su Yeon Kang
Managing Director · since 2022
Hong Gi Kim
Managing Director · since 2024
Yun Hwan Son
Internal Auditor · since 2014
Gi Wung Yoo
Managing Director · since 2024
Deok Jung Yoon
Assistant Managing Director
Heung Ju Oh
Vice Chairman · since 2022
Jun Ho Song
Co-President, Chief Executive Officer, Director · since 2022
IPO date
May 29, 2007
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT